Tanaka, Tomoaki

Phosphate-activated glutaminase (GLS2), a p53-inducible regulator of glutamine metabolism and reactive oxygen species

Suzuki, S., Tanaka, T., Poyurovsky, M. V., Nagano, H., Mayama, T., Ohkubo, S., Lokshin, M., Hosokawa, H., Nakayama, T., Suzuki, Y., et al. (2010) · Proceedings of the National Academy of Sciences

Cancer, Hypoxia, and MetabolismCancer-related Molecular Pathways

Cited by 705

Transcription factor PU.1 represses and activates gene expression in early T cells by redirecting partner transcription factor binding

Hosokawa, H., Ungerbäck, J., Wang, X., Matsumoto, M., Nakayama, K. I., Cohen, S. M., Tanaka, T., & Rothenberg, E. V. (2018) · Immunity

Genomics and Chromatin DynamicsT-cell and B-cell Immunology

Cited by 116

New diagnostic criteria of adrenal subclinical cushing's syndrome: Opinion from the Japan endocrine society

Yanase, T., Oki, Y., Katabami, T., Otsuki, M., Kageyama, K., Tanaka, T., Kawate, H., Tanabe, M., Doi, M., Akehi, Y., et al. (2018) · Endocrine Journal

Adrenal and Paraganglionic TumorsAdrenal Hormones and Disorders

Cited by 90

Liver lipid droplet cholesterol content is a key determinant of metabolic dysfunction–associated steatohepatitis

Sakuma, I., Gaspar, R. C., Nasiri, A. R., Dufour, S., Kahn, M., Zheng, J., LaMoia, T. E., Guerra, M. T., Taki, Y., Kawashima, Y., et al. (2025) · Proceedings of the National Academy of Sciences

Liver Disease Diagnosis and TreatmentCholesterol and Lipid Metabolism

Cited by 46

A multicenter, phase 2 study to evaluate the efficacy and safety of osilodrostat, a new 11β-hydroxylase inhibitor, in Japanese patients with endogenous Cushing's syndrome other than Cushing's disease

Tanaka, T., Satoh, F., Ujihara, M., Midorikawa, S., Kaneko, T., Takeda, T., Suzuki, A., Sato, M., & Shimatsu, A. (2020) · Endocrine Journal

Pituitary Gland Disorders and TreatmentsAdrenal Hormones and Disorders

Cited by 44